Data highlight potential of first-in-class CD8
Treg modulator
Phase 1 clinical trial underway to evaluate
MTX-101 in healthy adults and patients with celiac disease or type
1 diabetes
SEATTLE, June 21,
2024 /PRNewswire/ -- Mozart Therapeutics, a clinical
stage biopharmaceutical company focused on the development of
CD8 Treg modulators for the treatment of autoimmune diseases,
today presented new preclinical data on the Company's lead program,
MTX-101. The data were reviewed during an oral presentation at the
2024 American Diabetes Association 84th Scientific
Sessions, held June 21–24 in Orlando,
FL.
Courtney Crane, Ph.D., Senior
Vice President of Research at Mozart Therapeutics, presented data
supporting the relevance of therapeutic modulation of the
regulatory CD8 T cell network in autoimmune disease, including type
1 diabetes (T1D). Additionally, data from in vitro studies using
T1D-derived PBMC demonstrate that treatment with MTX-101 increases
the prevalence of CD8 Treg and that the functionality of CD8 Treg
(i.e., activation and cytolytic capacity) can be restored in this
autoimmune setting.
"We are pleased to highlight this new preclinical data on
MTX-101 in type 1 diabetes," said Dr. Crane. "These data support
the ability of MTX-101 to restore CD8 Treg function in autoimmune
disease. We look forward to evaluating this candidate in patients
with type 1 diabetes mellitus during Part B of our ongoing Phase 1
study".
About MTX-101
MTX-101 is a bispecific antibody targeting inhibitory KIR and
CD8 expressed on regulatory CD8 T cells. This autoimmune
checkpoint inhibitor aims to restore the intrinsic functions of
regulatory CD8 T cells, acting early in the autoimmune disease
process to suppress and eliminate pathogenic cells, halt downstream
inflammation, and prevent tissue destruction.
MTX-101 is currently being evaluated in a randomized, blinded,
placebo-controlled Phase 1 clinical study (NCT06324604) in healthy
adults (study Part A) and in patients with celiac disease or type 1
diabetes mellitus (study Part B).
About Mozart Therapeutics
Mozart Therapeutics is focused on developing first-in-class
disease-modifying therapies for autoimmune diseases, utilizing a
novel approach to restoring immune system function by targeting the
CD8 T regulatory network. The company is headquartered in
Seattle, WA. For more information,
visit www.mozart-tx.com and follow the company on LinkedIn
@Mozart–tx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mozart-therapeutics-announces-oral-presentation-on-mtx-101-at-the-2024-american-diabetes-associations-84th-scientific-sessions-302178524.html
SOURCE Mozart Therapeutics